Page last updated: 2024-09-05

erlotinib hydrochloride and Hematologic Malignancies

erlotinib hydrochloride has been researched along with Hematologic Malignancies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hampton, T	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Hematologic Malignancies

Article	Year
New blood cancer therapies under study. JAMA, 2007, Feb-07, Volume: 297, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab	2007

Article

Year

New blood cancer therapies under study.

JAMA, 2007, Feb-07, Volume: 297, Issue:5

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab

2007